NCT04924075
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04924075
Title Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2alpha Related Genetic Alterations (MK-6482-015)
Acronym MK-6482-015
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries USA | TUR | SWE | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS


No variant requirements are available.